AntiviralPK
Meeting category
Date(s)
11 Sep 2023 - 13 Sep 2023
Location
Rome, Italy
Meeting type
Hybrid Meeting

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2023

Related Enduring Materials

Enduring Materials
Virtual Program Book Antiviral PK 2023
Virtual Abstract Book Antiviral PK 2023

Day 1 - Monday, 11 September 2023

- 14:00
Opening Lecture: News in Antiviral Pharmacology: A Year in Review
Andrea Calcagno, MD, DTM&H
University of Turin, Italy
The Use of AI in Clinical Pharmacology
Session 1: Perspectives on the Role of ARV TDM in Clinical Pharmacology -
Is TDM Still Needed / Useful ?
Nancy Sheehan, PharmD, MSc
Université de Montréal and McGill University Health Centre, Canada
Minh Patrick Le, PharmD, PhD
University of Paris Cité, Bichat-Claude Bernard Hospital, France
Session 2: Special Topics in Clinical Pharmacology - Key Populations -
New(er) Antiretrovirals in Pregnancy and Breastfeeding
Catriona Waitt, MBChB, PhD
University of Liverpool, United Kingdom
Pharmacokinetics of Sofosbuvir-Based Direct Acting Antivirals for HCV in Pregnancy
Catherine Chappell, MD, MSc
University of Pittsburgh, United States
Abstract Oral Presentation #1: Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People with HIV
Mattia Berton
University Hospital Basel, Switzerland
Abstract Oral Presentation #2: Pharmacokinetic Data of Atazanavir/Ritonavir in Second-Line Treatment of Children Living with HIV: Results from the CHAPAS4-trial.
Anne Kamphuis
Radboud University Medical Center, The Netherlands

Day 2 - Tuesday, 12 September 2023

Session 3: Next-Generation Therapeutics – Long Acting Drugs -
Knowledge Gaps and Future Perspectives for Treatment Based on Long-Acting Technology
Andrew Owen, BSS, MSC, PhD, FSB
University of Liverpool, United Kingdom
A Year of CAB/RPV Use, What Have We Learned in the Real World
Emma Rubenstein, MD, MPH
Hôpital Saint-Louis, France
Abstract Oral Presentation #3: Preliminary Results of Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a Large National Cohort of People Living with HIV (ANRS-MIE-CARLA Study).
Caroline Solas Chesneau, PharmD, PhD
University Hospital of La Timone, Aix-Marseille University, France
Session 4: Abstract-Driven Session on Clinical Pharmacology on Pregnancy and HIV -
Abstract Oral Presentation #5: Intracellular Tenofovir-Diphosphate Concentrations with Tenofovir Alafenamide During Pregnancy and Postpartum in People with HIV: Results from IMPAACT 2026
Kristina Brooks, PharmD
University of Colorado Anschutz Medical Campus, United States
Abstract Oral Presentation #6: Temporal Changes in Dolutegravir and Raltegravir Glucuronide Metabolite to Parent Ratios during Pregnancy and Postpartum
Tim Cressey, MSc, PhD
Chiang Mai University, Thailand
Abstract Oral Presentation #7: Lower Exposure to Bictegravir in Third Trimester in Pregnant Women Living with HIV
Lena Van Der Wekken
Radboudumc, The Netherlands
Abstract Oral Presentation #8: Prediction of Maternal Pharmacokinetic of Bictegravir in Pregnancy Using Physiologically-Based Pharmacokinetic Modeling
Jeihun Kuack,
U.S. Food And Drug Administration, United States
Session 5: Challenges in Managing Complex Drug - Drug Interactions -
Management of Antiplatelet/DOAC DDIS (Pk/PD) - in Context of HIV, HCV, COVID Antiviral Therapy
Mike Emerson, PhD
Imperial College London, United Kingdom
Short Versus Extended Nirmatrelvir/R Treatment Course and Ensitrelvir: How Do DDIs Differ?
Catia Marzolini, PharmD, PhD
University Hospital of Basel, University Hospital of Lausanne, Switzerland; University of Liverpool, United Kingdom
Case Presentation - Complex DDI case
Dario Cattaneo, PharmD, PhD
Luigi Sacco University Hospital, Italy
Case Presentation - Complex DDI case
Giovanni Di Perri, MD, PhD
University of Turin, Italy
Session 6: Drug Interactions: PBPK Modelling and Pharmacodynamic Outcomes -
A (PK) Study in Scarlet: Investigating Target Concentrations​
Paolo Denti, PhD
University of Cape Town, South Africa
Abstract Oral Presentation #9: Physiologically Based Pharmacokinetic Modeling of Lenacapavir Pharmacokinetics and Model Validation with Drug-Drug Interactions Between Lenacapavir with Voriconazole or Rifampicin
Naveed Shaik
Gilead Sciences, Inc., United States
Abstract Oral Presentation #10: Dolutegravir But not Bictegravir Exposure Increases in Vitro Platelet Aggregation
Renos Keniyopoullos
Imperial College London, United Kingdom
Abstract Oral Presentation #11: Genetic Variants Influencing Neuroinflammation Biomarkers in Different Clinical Groups of People Affected by HIV
Jessica Cusato
University of Turin, Department of Medical Sciences, Italy
Session 7: DDI Guidance: Regulatory Landscape and Challenges with Emerging/New Compounds -
Harmonization of DDI Guidelines Among Different Regulatory Agencies: Challenges and Opportunities
Elin Lindhagen, MSci Pharm, PhD
Swedish Medical Products Agency, Sweden
A Global Collaboration to Harmonize Guidelines for Clinical Management of Ritonavir-Boosted Nirmatrelvir DDIs
Alice K. Pau, PharmD, FIDSA
National Institute of Allergy and Infectious Disease, National Institutes of Health, United States
Abstract Oral Presentation #12: Nirmatrelvir/Ritonavir Real World Drug-Drug Interaction Management Experience.
Shahid Bukhari
Chelsea & Westminster Hospital, United Kingdom
Abstract Oral Presentation #13: A Retrospective Descriptive Study of the Management and Consequences of Drug-Drug Interactions between Nirmatrelvir/Ritonavir and Systemic Treatment for Cancer
Samantha Robertson
Kingston Health Sciences Centre, Canada
Abstract Oral Presentation #14: Management of Drug-Drug Interaction and Safety of Oral Anticoagulants with Nirmatrelvir-Ritonavir
Pierre Giguere
The Ottawa Hospital, Canada

Day 3 - Wednesday, 13 September 2023

Session 8: Pharmacologic Data on New and Pipeline Drugs - Industry Session -
Gilead Sciences
Ramesh Palaparthy, PhD
Gilead Sciences, United States
GSK - ViiV Healthcare
Jon Collins, PharmD
ViiV Healthcare, United States
Shionogi Inc.
Simon Portsmouth, MBChB, MD, FRCP
Shionogi Inc., United States
Atea Pharmaceuticals, Inc.
Xiao-Jian Zhou, PhD
Atea Pharmaceuticals, Inc., United States
Session 9: Abstract-Driven Session on Innovative Tools to Assess Drug Exposure and Adherence -
Abstract Oral Presentation #15: Adherence Blood Sampling Devices Are Not All Created Equal: A Comparative Investigation
Amanda Schauer
University of North Carolina-Chapel Hill, United States
Abstract Oral Presentation #16: PrEP at the Site-of-Action in Transgender Women: A Pharmacology Study of Blood and Rectal CD4+ T Lymphocytes
Mackenzie L. Cottrell, PharmD
University of North Carolina, Chapel Hill, United States
Abstract Oral Presentation #17: Saliva, Tear and Nasal PK of Ritonavir-boosted Nimatrelvir (Paxlovid) in Combination with Molnupiravir in Patients with Laboratory Confirmed COVID-19
Laura Dickinson, PhD
University of Liverpool, United Kingdom
Abstract Oral Presentation #18: A Novel Approach to Identify PK Determinants of Efficacy: Implications for HIV-1 Latency Reversal by Romidepsin
Lauren Tompkins
The University of North Carolina at Chapel Hill, United States
Charles Boucher Memorial Session: The Role of Tissue Pharmacology in Response and Cure -
Tissue-Specific Pharmacology: Knowledge and Knowledge Gaps
Charles Flexner, MD
Johns Hopkins University School of Medicine, United States
Tissue-Specific Pharmacology: How Clinically Important Is It
Saye Khoo, MD, PhD
Royal Liverpool University Hospital; University of Liverpool, United Kingdom
Overview
Welcome

The International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2023 took place as a hybrid workshop from 11-13 September 2023 in Rome, Italy.

The International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs gathers leading experts to discuss all aspects of the optimal use of antiviral therapy including drug-drug interactions, pharmacokinetics of investigational and existing drugs, pharmacodynamics, drug dosing in underrepresented populations, post-marketing surveillance, and regulatory considerations.
 

Program Chairs 2023
General Information 
COVID-19 Update
Responding to the changing COVID-19 situation, the International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2023 will be held as a hybrid meeting allowing both in-person and virtual attendance. This workshop format is an optimal solution in light of the current circumstances.

We are available to answer any questions or concerns that you may have about your participation. For more information, please contact Michelle Wu via Michelle.Wu@amededu.com.
Who Should Attend?
- Clinical pharmacologists;

- Pharmacists;

- Clinicians/ researchers;

- Industry representatives;

- Regulatory scientists;

- Government representatives;

- Post-graduate students; and

- Others involved in the clinical pharmacology of antiviral therapy.
Meeting Objectives
This meeting aims to:

- Gather experts involved in clinical pharmacology from different disciplines in an interactive workshop setting;

- Provide a platform for presentation and discussion of the latest developments in the field;

- Share information on ongoing pharmacological studies; and

- Stimulate discussion and consensus on best practices.
Learning Objectives
After participating in this activity, participants will be able to:

- Outline new developments and the clinical pharmacology of antiviral therapies for HIV, COVID-19, Hepatitis, and other viruses;

- Reflect on new Drug Detection / Delivery Technologies; and

- Describe pharmacological considerations in key populations.
Practical Information 
Venue
Address:
Roma Eventi Fontana Di Trevi
Piazza della Pilotta, 4
00187 Roma
Italy

Distance from Leonardo da Vinci International Airport (FCO): 31 km
Networking Dinner
The confirmed restaurant for the Networking Dinner of the Antiviral PK Workshop 2023 is at the following:        

        Nanà Vini e Cucina
        Via della Panetteria, 37
        00187 Roma RM
       ​​​​​​​ ​​​​​Italy

Distance from the workshop venue: 350 m (4-min walking)

The Networking Dinner is not included in the registration fee. Should you wish to attend the Networking Dinner, an additional fee of €60 is charged. Pre-booking is required via the conference secretariat.
Badges
All participants are requested to wear the badge at all times during the conference to ensure admission to the meeting.
Certificate of Attendance
A certificate of attendance will be sent to participants after they have successfully completed the program and post-meeting survey.
Language
The official language of the workshop is English. Translation will not be provided.
Enduring Materials
Conference materials can be obtained upon registration at the registration desk at the Conference Venue.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Academic Medical Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Academic Medical Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the workshop, participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official workshop sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of AME-organized programs are expected to treat others with dignity and respect at all times.

Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to AME via info@amededu.com or to one of our on-site personnel.

Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Registration
Registration is now closed.
Fees and Conditions

Regular Delegates

In-Person Attendance

Regular Delegates

Virtual Attendance

Industry***

Early Fee (payment before/on 14 May 2023) 

€ 395.00

€ 197.50

€ 1,345.00

Standard Fee (payment before/on 10 September 2023)

€ 795.00

€ 397.50

€ 1,745.00

Same-Day Fee* (payment from 11 September 2023)

€ 995.00

€ 497.50

€ 1,945.00

Discounts

Early-career investigators /Regular Delegates from Resource-Limited Settings (RLS)** WITH ACCEPTED ABSTRACT

Complimentary Registration

Early-Career Investigators /Regular Delegates from Resource-Limited Settings (RLS)** WITHOUT ACCEPTED ABSTRACT

50% Off Current Regular Delegate Fee

NGO Representatives / Government Representatives (i.e. MOH, NIH, NIAID, etc.) / Advocates

50% Off Current Regular Delegate Fee

Representatives of sponsoring industry / endorsing organizations ***

Please contact the conference secretariat

* To register on the workshop dates and revisit the recordings of the live stream on the virtual portal.

** Countries included in the low-income and lower-middle-income economies of the World Bank Classification.

*** Industry and endorser representatives may receive a discount based on the level of support provided to the event. For more support and registration information, please contact us via Jesper.Niesen@amededu.com

If you have financial concerns or are eligible for a discount, please contact the conference secretariat via Michelle.Wu@amededu.com.

Important
  • Please find below the AIFA Authorization procedure.
  • We strongly advise that you register early to secure your slot. 
  • Submission of your online registration does not guarantee that your registration has been accepted. Your registration is final when full payment has been received (if applicable) and a confirmation of your registration has been sent.
Registration Fee Includes
For onsite attendees, including Regular Delegates In-Person Attendees and Industry Representatives In-Person Attendees:

- Access to all scientific sessions, including poster area

- Conference pack, including virtual abstract book and printed program book

- Refreshments during the coffee breaks

- Buffet lunch on meeting days

- Complimentary entrance to the Networking Reception*

* The Networking Reception will take place in the same venue of the meeting, at Roma Eventi Fontana Di Trevi, and will not have any music / entertainment of any shape or form. The Networking Reception only offers finger foods and the opportunity to have a look at the chosen abstract poster presentations.


For virtual attendees, including Regular Delegates Virtual Attendees and Industry Representatives Virtual Attendees only:

- Access to all scientific sessions

- Digital workshop pack, including the digital program book and digital abstract book.


IMPORTANT:

- No day rate is available

- The Networking Dinner is not included in the registration fee. Should you wish to attend the Networking Dinner, an additional fee of €60 is charged. Pre-booking is required via the conference secretariat. Please see the "General" Tab for more information about the Networking Dinner.

- Virology Education reserves the right to cancel improper registrations. Claims for a refund will not be honored.
Group Registration
For registration of groups larger than 5 participants, please contact the Conference Secretariat at Michelle.Wu@amededu.com.
Early-Career Investigators / Academia from Resource-limited Settings (RLS)
We are pleased to offer complimentary registration to early-career investigators and academia from low-income and lower-middle-income countries with an accepted abstract and a 50% discount on the registration fee without an accepted abstract.

IMPORTANT: Complimentary registration is offered to the presenting author only.

To be eligible as an early-career investigator, one should either be a current Master/PhD student or have obtained an MD/PharmD/PhD degree in the last five years. An application form needs to be completed by a supervisor and received by the Virology Education secretariat at least two weeks prior to the start of the workshop. Virology Education will contact the early-career investigator with instructions regarding the registration procedure.
AIFA Authorization Procedure
Any local or international pharmaceutical companies who wish to participate in this workshop should submit a request for authorization to AIFA (Italian Medicines Agency) per article 124 of Italian legislative decree 219 / 2006.

Local and international pharmaceutical companies are required to obtain authorization from AIFA. Requests to AIFA must be submitted 60 days before the workshop. Complete information regarding this process is available on the AIFA website: https://www.aifa.gov.it/en/acc

Should you require assistance submitting your application to AIFA, please get in touch with Fargo International with the company’s SIS code. They will assist you with the application process.

International companies with affiliates in Italy are recommended to contact their local offices, as they are informed about this procedure and can provide assistance if required.
Payment
By credit card only: online or by written authorization.

Please contact the conference secretariat via Michelle.Wu@amededu.com if you need to make alternative arrangements.
Cancellation Policy
In case of cancellation, the following refunds are applicable:

- Cancellation before/on 14 August 2023: 50% refund (minus an administration fee of €40)
- Cancellation after 14 August 2023: Unfortunately, no refund will be given

Should you be unable to attend the forum, a substitute delegate is always welcome at no extra charge provided that a letter of authorization from the original participant has been received and the conference secretariat has been notified of the name of the substitute delegate before 28 August 2023. A statement (email/letter) of your cancellation must be sent to Virology Education.
Liability and Insurance
By registering for the meeting, participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance. Participants are advised to take out their own insurance policies.
Media Registration
In order to register as a media participant for the workshop, the conference secretariat needs to receive:

1. Proof of accreditation
2. Valid identification (e.g. passport)
3. A letter from your assignment giver stating the details of your assignment (e.g. editor)
4. At least 3 previous written assignments in recognized outlets on HIV. If you are a freelance journalist, the assignments can be from different (recognizable) news outlets. Links to online publications are accepted
5. The website of the publication(s)/blog(s) that will be featuring your story on this workshop

A complimentary or reduced registration fee may apply for accredited media participants depending on availability. Preference will be given to credible print and online news sources. Please contact the conference secretariat for registration conditions.

We would like to receive a copy of your workshop report/ article once it is finalized.
All credentials will be verified by the Organizing Committee of the Workshop. Media representatives are kindly requested to register by sending the above-mentioned information to info@amededu.com.

Important: Media is restricted to the written press. Recording on film or photo is not allowed. Academic Medical Education will request a copy of the written piece once it is finalized. Media representatives must also agree to abide by the 2023 embargo policy.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The organizing secretariat of this workshop, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop. In case of cancellation of the meeting due to unforeseen circumstances, Virology Education cannot be held responsible for expenses made for travel, accommodation, visa applications, etc.
Committees
Chairs 2023
Organizing Committee

The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.

Scientific Committee

The members of Scientific Committee are hand-picked by the Organizing Committee and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.

  • Su-Young Choi, PharmD, PhD - Food and Drug Administration, United States
  • Angela Colbers, PhD  - Radboud University Medical Center, the Netherlands
  • Rodolphe Garraffo, MD - Hopital Pasteur Nice, France
  • David Haas, MD - Vanderbilt University Medical Center, United States
  • Saye Khoo, MD - University of Liverpool, United Kingdom
  • Mohammed Lamorde, MD - Infectious Diseases Institute, Uganda
  • Lawrence Lee, MBBS, PhD - National University of Singapore, Singapore
  • Minh Patrick Lê, PhD - Hôpital Bichat-Claude Bernard, France
  • Catia Marzolini, PharmD, PhD - University Hospital Basel & University of Liverpool, United Kingdom
  • Kimberly Struble, PharmD - Food and Drug Administration, United States
  • Steve Taylor, MRCP, PhD - Birmingham Heartlands Hospital, United Kingdom
  • Catriona Waitt, MBChB, PhD - University of Liverpool, United Kingdom 
Academic Advisory Board

The members of the Academic Advisory Board (AAB) are former members of the OC and remain active the in planning of the program for the next year. Members of the current OC are selected from this group. 

  • David Back, PhD - University of Liverpool, United Kingdom
  • Terrence Blaschke, MD - Stanford University School of Medicine, United States
  • David Burger, MD, PhD - Radboud University Medical Center, the Netherlands
  • Giovanni Di Perri, MD, PhD - University of Torino, Italy
  • Courtney Fletcher, PharmD - University of Nebraska Medical Center, United States
  • Charles Flexner, MD - Johns Hopkins University, United States
  • Angela Kashuba, PharmD - University of North Carolina at Chapel Hill, United States
  • Jennifer Kiser, PharmD, PhD - University of Colorado, United States
  • Jürgen Rockstroh, MD - University of Bonn, Germany
  • Jonathan Schapiro, MD - National Hemophilia Center, Sheba Medical Center, Israel
Industry Liaison Board

The Industry Liaison Board, consisting of leading medical scientists of the pharmaceutical industry, is asked to give input and suggestions that help the Organizing Committee in planning the workshop and providing support on topics of interest and innovative suggestions to optimize audience participation. The Industry Liaison Board assists the Organizing Committee by suggesting the most current and critical topics to bring the audience up-to-date on the most current research in the pharmaceutical industry in related disciplines.

  • Wei Liu - AbbVie
  • Thomas Kakuda - Alios BioPharma
  • Charles LaPorte - Janssen Biologics
  • Marco Siccardi - Labcorp
  • Daria Hazuda - Merck
  • Manoli Vourvahis - Pfizer
  • Parul Patel - ViiV Healthcare

Abstracts
Abstract Submission Portal is Now Closed
Abstracts
  • Abstract Submission Portal is closed.
     
  • Registration fees are waived for healthcare professionals from RLS and early-career professionals with an accepted abstract. A 50% discount is offered to healthcare professionals from RLS and early-career professionals without an accepted abstract. The requirements for the application are specified under "Registration".
  • Abstracts can be submitted in English.

  • Abstract submitters are encouraged to use person-first language in their abstracts. View our guidelines here

Image
meeting 1
Categories for Abstract Submission
We invite you to submit your latest study and data in any of the below categories: 

- Drug-Drug Interactions

- Novel Drugs and Formulations

- Pharmacogenetics

- Pharmacokinetics during Pregnancy and Other Key Populations

- PK/PD of Drug Efficacy and Toxicity (including TDM)

- Cellular and Tissue Pharmacokinetics
General Guidelines
Abstracts should contain the following four components:

- Background: A concise statement of the issue under investigation or a hypothesis;

- Material and Methods: The experimental methods used (including the statistical analyses employed);

- Results: Specific findings (promises such as "to be completed" or "to be presented" are not acceptable);

- Conclusions: A summary of findings that are supported by your results (statistical analyses used to support the conclusions, where appropriate, should be included; concluding statements such as "the results will be discussed" are not acceptable).

Please note that abstracts cannot be accepted if tables or graphs are included. The maximum word count for the abstract body is 500 words.

Abstracts are considered official communications to the conference and will be treated confidentially. Submitters of accepted abstracts agree to attend the meeting and present their abstract as scheduled.
Abstract Submission
Authors can submit their abstracts electronically until 30 June 2023. You will be redirected to the submission website. Please follow the step-by-step directions to upload the abstract. To ensure your abstract retains any special characters or formatting, the abstract must be in Microsoft Word format.
Support
Platinum Level

 Support provided by ViiV Healthcare.

Silver Level

Supported by Gilead who provided funding. Gilead has had no input into the content of the materials used at this meeting/conference.

Support Our Initiative

Financial backing to the International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2023 helps us deliver an impactful meeting experience for the benefit of healthcare professionals, researchers, and community representatives involved in clinical pharmacology of HIV, Hepatitis, and other antiviral drugs.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.

To show your commitment to the cause, get in touch with us for a tailored support package by contacting Jesper Niesen at Jesper.Niesen@amededu.com or call +31 30 230 7140.
 
Benefits of Support
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.

  • Symposium opportunities
  • Non-commercial interviews with company representatives
  • Verbal acknowledgement during the program 
  • Discounted and complimentary registrations for your representatives
  • Company acknowledgement on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
  • Company acknowledgement on printed meeting materials including but not limited to banners and the program book
  • Digital and printed advertising opportunities 
  • Social media shout-outs
  • Logo on the conference bag 

 
*Subject to the support level.

Endorsers
Venue
Venue

The confirmed venue details for the International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2023 can be found below.

  • Website: Roma Eventi Fontana Di Trevi 
  • Website: www.roma-eventi.com/ita/fontana-di-trevi
  • Address: Piazza della Pilotta, 4, 00187 Roma, Italy (please click here to view the map).
  • Distance from Leonardo da Vinci International Airport (FCO): 31 km

In case you have any questions or concerns regarding the venue, please feel free to contact us at Michelle.Wu@amededu.com

Media
Photos
International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2023 | 11-13 September 2023

Invitation from Kimberly Scarsi, PharmD, MS, FCCP, University of Nebraska Medical Center (UNMC), United States and Alice Tseng, B.Sc.Phm., PharmD, FCSHP, AAHIVP, University of Toronto, Canada

Previous Editions